Cargando…

Urine miR-21-5p as a potential biomarker for predicting effectiveness of tadalafil in benign prostatic hyperplasia

AIM: To investigate whether urine levels of miRNAs that regulate the function of endothelial cells are associated with effectiveness in benign prostatic hyperplasia (BPH) patients treated with a phosphodiesterase type 5 inhibitor, tadalafil. PATIENTS & METHODS: We measured urine levels of three...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Tomoaki, Minami, Akinori, Tashiro, Kouichiro, Yoshida, Naomasa, Tohda, Akira, Yamakoshi, Yasuo, Yasumoto, Ryoji, Sugita, Shozo, Nakatani, Tatsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Science Ltd 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060390/ https://www.ncbi.nlm.nih.gov/pubmed/30057782 http://dx.doi.org/10.4155/fsoa-2018-0012

Ejemplares similares

Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies
por: Angalakuditi, Mallik, et al.
Publicado: (2010)

Meta-Analysis of Efficacy and Safety of Tadalafil Plus Tamsulosin Compared with Tadalafil Alone in Treating Men with Benign Prostatic Hyperplasia and Erectile Dysfunction
por: Zhou, Zhongbao, et al.
Publicado: (2019)

Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus
por: Elkelany, Osama O, et al.
Publicado: (2015)

The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction
por: Gacci, Mauro, et al.
Publicado: (2013)

Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations
por: Alsaikhan, Bader, et al.
Publicado: (2014)

Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride
por: Kosilov, Kirill V., et al.
Publicado: (2020)

Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia
por: Gotoh, Daisuke, et al.
Publicado: (2022)

Tadalafil vs. tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a prospective, randomized study
por: Pogula, Vedamurthy Reddy, et al.
Publicado: (2019)

Attenuation of Benign Prostatic Hyperplasia by Optimized Tadalafil Loaded Pumpkin Seed Oil-Based Self Nanoemulsion: In Vitro and In Vivo Evaluation
por: Alhakamy, Nabil A., et al.
Publicado: (2019)

Comparative study of tamsulosin versus tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms. A prospective randomized study
por: Ahmad, Malik Suhail, et al.
Publicado: (2022)

Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations
por: Lee, Lulu K, et al.
Publicado: (2016)

Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: A randomized double blind placebo controlled cross-over study
por: Pattanaik, Smita, et al.
Publicado: (2019)

Bacteriology of Urine Specimens Obtained from Men with Symptomatic Benign Prostatic Hyperplasia
por: Agbugui, Jude Orumuah, et al.
Publicado: (2016)

Histopathological and Immunohistochemical Study of Atypical Lymphoid Hyperplasia and Benign Lymphoid Hyperplasia of the Stomach
por: Takano, Yasuo, et al.
Publicado: (1992)

The Efficacy and Safety of Tadalafil 5 mg Once Daily in Korean Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: An Integrated Analysis
por: Lee, Sung Won, et al.
Publicado: (2014)

Erratum: Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: A randomized double blind placebo controlled cross-over study
Publicado: (2019)

Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil
por: Park, Hyun Jun, et al.
Publicado: (2013)

Comparative Effectiveness of Tadalafil versus Tamsulosin in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: A Meta-Analysis of Randomized Controlled Trials
por: Guo, Boda, et al.
Publicado: (2020)

Real-World Safety and Effectiveness of Tadalafil in Patients with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Japanese Post-Marketing Surveillance Study
por: Yamazaki, Hiroyoshi, et al.
Publicado: (2020)

Efficacy and Safety of 12-week Monotherapy With Once Daily 5 mg Tadalafil for Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: Evidence-based Analysis
por: Cui, Jianwei, et al.
Publicado: (2021)

Green & Sensitive pH-dependent Spectrofluorimetric Assay of Tamsulosin Hydrochloride and Tadalafil in their New Combined Formulation for Benign Prostatic Hyperplasia: Application to Spiked Human Plasma
por: Abdel Moneim, Mona M.
Publicado: (2022)

Management of benign prostatic hyperplasia with silodosin
por: Yamanishi, Tomonori, et al.
Publicado: (2009)

Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia
por: AbdelRazek, Mostafa, et al.
Publicado: (2022)

Extravasation of Urine Associated with Bilateral Complete Ureteral Duplication, Vesicoureteral Reflux and Benign Prostatic Hyperplasia
por: Suzuki, Issei, et al.
Publicado: (2017)

Benign Prostatic Hyperplasia
Publicado: (2015)

Predictors of Individual Response to Placebo or Tadalafil 5mg among Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: An Integrated Clinical Data Mining Analysis
por: Fusco, Ferdinando, et al.
Publicado: (2015)

Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction
por: Ahn, Sun Tae, et al.
Publicado: (2020)

Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia
por: Yoshida, Masaki, et al.
Publicado: (2011)

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Tamsulosin Plus Tadalafil Compared With Tamsulosin Alone in Treating Males With Lower Urinary Tract Symptoms Secondary to Benign Prostrate Hyperplasia
por: Zhou, Rui, et al.
Publicado: (2023)

Testosterone and benign prostatic hyperplasia
por: Jarvis, Thomas R, et al.
Publicado: (2015)

Maternal Blood Concentration of Tadalafil and Uterine Blood Flow in Pregnancy
por: Tanaka, Hiroaki, et al.
Publicado: (2019)

Large bowel obstruction caused by urinary retention from benign prostate hyperplasia
por: Fujisaki, Tomohiro, et al.
Publicado: (2018)

Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia
por: Jia, Gaozhen, et al.
Publicado: (2017)

Evaluation of Voiding Position on Uroflowmetry Parameters and Post Void Residual Urine in Patients With Benign Prostatic Hyperplasia and Healthy Men
por: Alrabadi, Adel, et al.
Publicado: (2020)

Tadalafil in the treatment of erectile dysfunction
por: Coward, Robert M, et al.
Publicado: (2008)

Myopathy with Concurrent Tadalafil and Simvastatin
por: Gargante, Maria Pia, et al.
Publicado: (2009)

Silodosin in the treatment of benign prostatic hyperplasia
por: Rossi, Maxime, et al.
Publicado: (2010)

Pathophysiology of clinical benign prostatic hyperplasia
por: Foo, Keong Tatt
Publicado: (2017)

Epidemiology of clinical benign prostatic hyperplasia
por: Lim, Kok Bin
Publicado: (2017)

Botulinum toxin and benign prostatic hyperplasia
por: Ng, Lay Guat
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vpmrk5hige19273ifiqgphubb5